Type 2-skewed atopic features in pediatric alopecia areata: evidence, candidate biomarkers, and treatment considerations in the JAK inhibitor era

Treatment options for pediatric alopecia areata (AA) are expanding, but treatment selection remains guided mainly by clinical severity, with limited biologic stratification. The established AA model centers on loss of hair follicle immune privilege, cytotoxic T-cell infiltration, interferon- γ (IFN- γ )/interleukin-15 (IL-15) signaling, and downstream Janus kinase–signal transducer and activator of transcription (JAK-STAT) activation. Some children also have atopic dermatitis (AD), asthma, or allergic rhinitis, together with elevated immunoglobulin E (IgE) or eosinophilia. We examine whether these clinical features have a counterpart in AA tissue and assess the directness of the pediatric evidence. Studies of lesional scalp in predominantly adult or mixed-age cohorts identify type 2-associated signals alongside the canonical cytotoxic axis, but do not establish a distinct pediatric endotype. Circulating IgE and eosinophils may reflect concomitant atopy; neither has been validated to diagnose AA, predict its course, or select treatment. JAK inhibitors remain the principal AA-directed systemic option when age, indication, severity, and monitoring requirements align. Dupilumab blocks the interleukin-4 receptor α (IL-4R α ) and may be considered for an independently indicated type 2 comorbidity, while its effect on AA in children remains exploratory. Prospective pediatric studies linking clinical atopy, lesional immune signatures, accessible markers, and treatment outcomes are needed before this proposed framework can guide care.

Authors

Institutions

Publication Details

Journal
Frontiers in Pediatrics
Published
2026-11-20
DOI
https://doi.org/10.3389/fped.2026.1939407
Primary Topic
Hair Growth and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Type 2-skewed atopic features in pediatric alopecia areata: evidence, candidate biomarkers, and treatment considerations in the JAK inhibitor era

Baoquan Qu, Lyu Shuying, Ying Wang, Nuo Li et al.
2 links
Frontiers in Pediatrics
Hair Growth and Disorders
article

Type 2-skewed atopic features in pediatric alopecia areata: evidence, candidate biomarkers, and treatment considerations in the JAK inhibitor era

Baoquan Qu, Lyu Shuying, Ying Wang, Nuo Li, Dingquan Yang
article en

Abstract

Treatment options for pediatric alopecia areata (AA) are expanding, but treatment selection remains guided mainly by clinical severity, with limited biologic stratification. The established AA model centers on loss of hair follicle immune privilege, cytotoxic T-cell infiltration, interferon- γ (IFN- γ )/interleukin-15 (IL-15) signaling, and downstream Janus kinase–signal transducer and activator of transcription (JAK-STAT) activation. Some children also have atopic dermatitis (AD), asthma, or allergic rhinitis, together with elevated immunoglobulin E (IgE) or eosinophilia. We examine whether these clinical features have a counterpart in AA tissue and assess the directness of the pediatric evidence. Studies of lesional scalp in predominantly adult or mixed-age cohorts identify type 2-associated signals alongside the canonical cytotoxic axis, but do not establish a distinct pediatric endotype. Circulating IgE and eosinophils may reflect concomitant atopy; neither has been validated to diagnose AA, predict its course, or select treatment. JAK inhibitors remain the principal AA-directed systemic option when age, indication, severity, and monitoring requirements align. Dupilumab blocks the interleukin-4 receptor α (IL-4R α ) and may be considered for an independently indicated type 2 comorbidity, while its effect on AA in children remains exploratory. Prospective pediatric studies linking clinical atopy, lesional immune signatures, accessible markers, and treatment outcomes are needed before this proposed framework can guide care.

Frontiers in PediatricsVol. 14
China-Japan Friendship Hospital (CN)
Good health and well-being
Hair Growth and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Type 2-skewed atopic features in pediatric alopecia areata: evidence, candidate biomarkers, and treatment considerations in the JAK inhibitor era — Baoquan Qu, Lyu Shuying, et al. · Frontiers in Pediatrics (2026) | TGRS Research Map | TGRS